Long-term suppression of recurrent herpes labialis by low-dose oral acyclovir in an immunocompromised patient

A patient with chronic lymphocytic leukemia and severe and frequently recurring herpes labialis received oral acyclovir for more than 18 months, during most of this period at a low dosage (400 mg/d). This regimen was fully successful in preventing recurrences, with no adverse effects.